Mixed Lineage Kinase Modulators
    2.
    发明申请
    Mixed Lineage Kinase Modulators 失效
    混合谱系激酶调节剂

    公开(公告)号:US20080113977A1

    公开(公告)日:2008-05-15

    申请号:US10535061

    申请日:2003-11-12

    CPC分类号: C07D487/04

    摘要: The present invention provides a compound of the formula: (Formula I); or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, comprising administering to a patient in thereof an effective amount of a compound of Formula I.

    摘要翻译: 本发明提供下式的化合物:(式I); 其药物组合物包含有效量的式I化合物与合适的载体,稀释剂或赋形剂的组合,以及用于治疗生理障碍,特别是充血性心脏病的方法,包括向其中的患者施用 有效量的式I化合物。

    PI3 kinase/mTOR dual inhibitor
    3.
    发明授权
    PI3 kinase/mTOR dual inhibitor 有权
    PI3激酶/ mTOR双重抑制剂

    公开(公告)号:US08440829B2

    公开(公告)日:2013-05-14

    申请号:US13347886

    申请日:2012-01-11

    IPC分类号: C07D471/04

    CPC分类号: A61K31/4745 C07D471/04

    摘要: The present invention provides an imidazo[4,5-c]quinolin-2-one compound, or a pharmaceutically acceptable salt thereof, that inhibits both PI3K and mTOR and, therefore, is useful in the treatment of cancer.

    摘要翻译: 本发明提供抑制PI3K和mTOR两者的咪唑并[4,5-c]喹啉-2-酮化合物或其药学上可接受的盐,因此可用于治疗癌症。